Christensen, A. V., Nielsen, I. M.: Dopaminergic supersensitivity: Influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia. Psychopharmacol. 62, 111–116 (1979)

Costall, B., Naylor, R. J., Olley, J. E.: Stereotypic and anticataleptic activities of amphetamine after intracerebral injections. Eur. J. Pharmacol. 18, 83–94 (1972)

Ezrin-Waters, C., Seeman, P.: L-dopa reversal of hyperdopaminergic behavior. Life Sci. 22, 1027–1032 (1978)

Friedhoff, A. J., Bonnet, K., Rosengarten, H.: Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa. Res. Commun. Chem. Pathol. Pharmacol. 16, 411–423 (1977)

Gianutsos, G., Drawbaugh, R. B., Hynes, M. D., Lal, H.: Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 14, 887–898 (1974)

Gnegy, M., Uzunov, P., Costa, E.: Participation of an endogenous Ca+2-binding protein activator in the development of druginduced supersensitivity of striatal dopamine receptors. J. Pharmacol. Exp. Ther. 202, 558–564 (1977)

List, S. J., Seeman, P.: Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats. Life Sci. 24, 1447–1452 (1979)

Muller, P., Seeman, P.: Dopaminergic supersensitivity after neuroleptics: Time. course and specificity. Psychopharmacol. 60, 1–11 (1978)

Quik, M., Iversen, L. L.: Subsensitivity of the rat striatal dopaminergic system after treatment with bromocriptine: Effects on 3H spiperone binding and dopamine-stimulated cyclic AMP formation. Naunyn Schmiedeberg's Arch. Pharmacol. 304, 141–145 (1978)

Smith, R. C., Davis, J. M.: Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine and thioridazine. Life Sci. 19, 725–732 (1976)